8 research outputs found
Enabling the Development and Deployment of Next Generation Point-of-Care Diagnostics
<p>Enabling the Development and Deployment of Next Generation Point-of-Care Diagnostics</p
Sex-Related Differences in Hematological Parameters and Organosomatic Indices of Oreochromis niloticus Exposed to Aflatoxin B1 Diet
A 24-week feeding experiment was conducted to assess whether males and females of Oreochromis niloticus exhibit differences in their hematological responses and organosomatic indices to dietary AFB1 contamination. Triplicate groups of O. niloticus (initial body weight: 24.1 ± 0.6 g) were fed with four diets (Diets 1 to 4) containing 0, 20, 200, and 2,000 μg AFB1 kg−1. A significant decrease (P<0.05) in hemoglobin (Hb), red blood cells (RBC), and hematocrit (Hct) was observed in AFB1 exposure groups, with the lowest levels recorded in the 2000 μg AFB1 kg−1 treatment. A significant increase in mean white blood cells (WBC), neutrophils, and lymphocytes was observed in AFB1 exposure groups. No sex-related differences in RBC, WBC, lymphocytes, monocytes, and neutrophils levels were observed. However, hemoglobin and hematocrit values for female O. niloticus were significantly lower than those for male O. niloticus. Organosomatic indices showed that the relative liver, kidney, and spleen weights were significantly higher (P<0.05) in the AFB1 supplemented group than in the control group. However, the effect of aflatoxin on organosomatic indices does not depend on sex but rather depends on the dose of aflatoxin in the diet. These results provide useful information for monitoring changes in the health status of male and female O. niloticus
Erythrina abyssinica prevents meningoencephalitis in chronic Trypanosoma brucei brucei mouse model
Human African trypanosomiasis is prevalent in Sub-sahara African countries that lie between 14° North and 29° south of the equator. Sixty million people are at risk of infection. Trypanosoma brucei gambesience occurs in West and Central Africa while Trypanosoma brucei rhodesience occurs in East and Southern Africa. The neurological stage of the disease is characterized by neuroinflammation. About 10% of patients treated with the recommended drug, melarsoprol develop post treatment reactive encephalopathy, which is fatal in 50% of these patients, thus melarsoprol is fatal in 5% of all treated patients. This study was aimed at establishing the potential activity of Erythrina abyssinica in reducing neuroinflammation following infection with Trypanosoma brucei brucei. Swiss white mice were divided into ten groups, two control groups and eight infected groups. Infected mice received either methanol or water extract of Erythrina abyssinica at 12.5, 25, 50 or 100 mg/kg body weight. Parasite counts were monitored in peripheral circulation from the third day post infection up to the end of the study. Brains were processed for histology, immunohistochemistry scanning and transmission electron microscopy. Following infection, trypanosomes were observed in circulation 3 days post-infection, with the parasitaemia occurring in waves. In the cerebrum, typical brain pathology of chronic trypanosomiasis was reproduced. This was exhibited as astrocytosis, perivascular cuffing and infiltration of inflammatory cells into the neuropil. However, mice treated with Erythrina abyssinica water extract exhibited significant reduction in perivascular cuffing, lymphocytic infiltration and astrocytosis in the cerebrum. The methanol extract did not have a significant difference compared to the non-treated group. This study provides evidence of anti-inflammatory properties of Erythrina abyssinica and may support its wide use as a medicinal plant by various communities in Kenya
Enabling the Development and Deployment of Next Generation Point-of-Care Diagnostics.
<p>Enabling the Development and Deployment of Next Generation Point-of-Care Diagnostics</p
Barriers and potential solutions to advancing POC diagnostics research.
<p>Barriers and potential solutions to advancing POC diagnostics research.</p
Devices demonstrated at the workshop.
<p>(*Devices were produced on site)</p><p>Devices demonstrated at the workshop.</p
Value chain of point-of-care diagnostics.
<p>The top part displays the stakeholders that are involved in the development, commercialization, roll out, and integration of point-of-care diagnostic tests into control and surveillance programs</p